Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.

ABSTRACT:

Study objective

To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) - a fixed-dose combination of an inhaled corticosteroid (ICS) and a long-acting β2 -agonist for the treatment of asthma and chronic obstructive pulmonary disease - after single and repeat administration in healthy Chinese subjects.

Design

Double-blind, placebo-controlled, single-site, randomized, four-way crossover study.

Setting

The Clinical Pharmacological Research Centre at Peking Union Medical College Hospital [PUMCH]) in Beijing, China.

Subjects

Sixteen healthy, nonsmoking Chinese adults.

Intervention

Subjects were randomized to receive FF/VI 50/25, 100/25, or 200/25 μg, or placebo once/daily in the morning, delivered by the El

SUBMITTER: Chen X 

PROVIDER: S-EPMC4744690 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature